Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin
Journal of Cutaneous Pathology · 2024
DOI: 10.1111/cup.14579 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cutaneous Pathology, 2024. Verfasst von Woo Cheal Cho und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Adenocarcinoma, Papillary, Antibodies, Monoclonal, Nectins, Neoplasms, Adnexal and Skin Appendage. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Enfortumab vedotin (EV) is an antibody‐drug conjugate directed against Nectin‐4 that is used to treat urothelial carcinoma. Nectin‐4 is inherently expressed in the skin and adnexal structures. Since therapeutic options for cutaneous adnexal carcinomas are limited, we sought to evaluate Nectin‐4 expression in adnexal carcinomas and benign adnexal neoplasms to identify tumors that are potentially targetable with EV.
Methods
Eight sebaceous carcinomas (seven periocular and one lymph node metastasis), eight digital papillary adenocarcinomas, seven squamoid eccrine ductal carcinomas, eight poromas, eight trichilemmomas, and seven sebaceous adenomas were subjected to immunohistochemical staining for anti‐Nectin‐4 antibody. H‐scores for Nectin‐4 expression were calculated.
Results
Benign adnexal neoplasms had a significantly lower mean (±SD) Nectin‐4 H‐score (142.6 ± 39.1) than did the adnexal carcinomas (198 ± 90.8; p = 0.006). Nectin‐4 was expressed in 91% (21/23) of adnexal carcinomas. Sebaceous carcinomas frequently exhibited high expression of Nectin‐4 (88% [7/8]), with a mean (±SD) H‐score (258.1 ± 58.4) significantly higher than those for digital papillary adenocarcinomas (197.5 ± 52.5; p = 0.035) and squamoid eccrine ductal carcinomas (131.4 ± 114.1; p = 0.031). Sebaceous carcinomas also had significantly higher H‐scores than did sebaceous adenomas (186.4 ± 25.0; p = 0.013).
Conclusions
Increased Nectin‐4 expression in a subset of cutaneous adnexal carcinomas, particularly sebaceous carcinomas, reveals that EV is a potential therapeutic option for these tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Orbital Oncology & Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Woo Cheal Cho, Priyadharsini Nagarajan, Phyu P Aung, Mario L Marques-Piubelli, Doina Ivan, Carlos A Torres-Cabala, Omar Alhalabi, Victor G Prieto, Jonathan L Curry
Zitieren
APA
Cho, W. C., Saade, R., Nagarajan, P., Aung, P. P., Milton, D. R., Marques-Piubelli, M. L., Hudgens, C., Ledesma, D., Nelson, K., Ivan, D., Zhang, M., Torres-Cabala, C. A., Campbell, M., Alhalabi, O., Prieto, V. G., Wistuba, I. I., Esmaeli, B., & Curry, J. L. (2024). Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14579
Vancouver
Cho WC, Saade R, Nagarajan P, Aung PP, Milton DR, Marques-Piubelli ML, et al. Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. Journal of Cutaneous Pathology. 2024. doi:10.1111/cup.14579
BibTeX
@article{Cho2024,
author = {Cho, Woo Cheal and Saade, Rayan and Nagarajan, Priyadharsini and Aung, Phyu P and Milton, Denái R and Marques-Piubelli, Mario L and Hudgens, Courtney and Ledesma, Debora and Nelson, Kelly and Ivan, Doina and Zhang, Miao and Torres-Cabala, Carlos A and Campbell, Matthew and Alhalabi, Omar and Prieto, Victor G and Wistuba, Ignacio I and Esmaeli, Bita and Curry, Jonathan L},
title = {Nectin‐4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin},
journal = {Journal of Cutaneous Pathology},
year = {2024},
doi = {10.1111/cup.14579}
}
EUVIMED